Abstract
The discovery of novel intervention points in the inflammatory pathway has been a focus of drug development in recent years. We have identified pathway selective ligands for the estrogen receptor (ER) that inhibit NF-kB mediated inflammatory gene expression causing a reduction of cytokines, chemokines, adhesion molecules and inflammatory enzymes. SAR development of a series of 4-(Indazol-3-yl)-phenols has led to the identification of WAY-169916 an orally active non-steroidal ligand with the potential use in the treatment of inflammatory diseases without the classical proliferative effects associated with non-selective estrogens.
Keywords: Estrogen receptor, ER, nuclear factor kappa B, NF-kB
Current Topics in Medicinal Chemistry
Title: Control of Chronic Inflammation with Pathway Selective Estrogen Receptor Ligands
Volume: 6 Issue: 2
Author(s): Robert J. Steffan, Edward Matelan, Mark A. Ashwell, William J. Moore, William R. Solvibile, Eugene Trybulski, Christopher C. Chadwick, Susan Chippari, Thomas Kenney, Richard C. Winneker, Amy Eckert, Lisa Borges-Marcucci, Steven J. Adelman, Zhang Xu, Lydia Mosyak and Douglas C. Harnish
Affiliation:
Keywords: Estrogen receptor, ER, nuclear factor kappa B, NF-kB
Abstract: The discovery of novel intervention points in the inflammatory pathway has been a focus of drug development in recent years. We have identified pathway selective ligands for the estrogen receptor (ER) that inhibit NF-kB mediated inflammatory gene expression causing a reduction of cytokines, chemokines, adhesion molecules and inflammatory enzymes. SAR development of a series of 4-(Indazol-3-yl)-phenols has led to the identification of WAY-169916 an orally active non-steroidal ligand with the potential use in the treatment of inflammatory diseases without the classical proliferative effects associated with non-selective estrogens.
Export Options
About this article
Cite this article as:
Steffan J. Robert, Matelan Edward, Ashwell A. Mark, Moore J. William, Solvibile R. William, Trybulski Eugene, Chadwick C. Christopher, Chippari Susan, Kenney Thomas, Winneker C. Richard, Eckert Amy, Borges-Marcucci Lisa, Adelman J. Steven, Xu Zhang, Mosyak Lydia and Harnish C. Douglas, Control of Chronic Inflammation with Pathway Selective Estrogen Receptor Ligands, Current Topics in Medicinal Chemistry 2006; 6 (2) . https://dx.doi.org/10.2174/156802606775270279
DOI https://dx.doi.org/10.2174/156802606775270279 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Gene-Diet Interactions in Childhood Obesity
Current Genomics Targeting Pathways Mediating Bone Disease
Current Pharmaceutical Biotechnology Roles of Interferon Induced Protein with Tetratricopeptide Repeats (IFIT) Family in Cancer
Current Medicinal Chemistry Amelioration of Cisplatin Induced Nephrotoxicity by Standardized Methanolic Extract of Roots of Boerhaavia diffusa
The Natural Products Journal Mast Cell's Role in Cytokine Release Syndrome and Related Manifestations of COVID-19 Disease
Current Pharmaceutical Design Virus-Like Particles as Particulate Vaccines
Current HIV Research Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Lithium and Kidney, 60 Years Later
Current Drug Safety Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Ischemic Brain Injury
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Mesenchymal Stem Cells in Immune Response
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Successful Structure-Based Design of Recent p38 MAP Kinase Inhibitors
Current Topics in Medicinal Chemistry Function and Molecular Mechanism of Tumor-Targeted Peptides for Delivering Therapeutic Genes and Chemical Drugs
Mini-Reviews in Medicinal Chemistry Immunometabolism Dysfunction in the Pathophysiology and Treatment of Rheumatoid Arthritis
Current Medicinal Chemistry The Role of Angiotensin Type 1 Receptor in Inflammation and Endothelial Dysfunction
Recent Patents on Cardiovascular Drug Discovery Meet Our Editorial Board Member
Current HIV Research Autism - A Comprehensive Array of Prominent Signs and Symptoms
Current Pharmaceutical Design Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Fenofibrate: Metabolic and Pleiotropic Effects
Current Vascular Pharmacology